Stockpiling smallpox virus

BMJ 2007; 334 doi: 10.1136/bmj.39177.580729.BE (Published 12 April 2007)
Cite this as: BMJ 2007;334:760

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Thomas Mack, professor of preventive medicine
  1. Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
  1. mack{at}ccnt.usc.edu

    Other viruses pose greater public health threats, so isn't it time to move on?

    Emotions still run high over the stocks of smallpox virus placed into the P4 freezers of Atlanta and Novosibirsk more than 30 years ago by the World Health Organization. In this week's BMJ, two articles present opposing views on whether the United States and Russia should destroy their stocks of smallpox virus (Variola).1 2

    One argument for maintaining smallpox stocks is that they are needed to develop safer vaccines.1 Our current effective vaccine is safe when used judiciously—not for mass vaccination of populations, but for targeting those at risk after screening out people with a history of HIV, leukaemia, or eczema at higher risk of complications after vaccination.3 Moreover, new vaccines are based on Vaccinia, not smallpox.4 No new vaccine can be tested for efficacy until human cases of smallpox reappear.

    Another argument is that smallpox stocks are needed to assess antiviral agents for the treatment of smallpox. Again, no agent can be properly tested until human cases reappear. …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL